Evaxion Biotech AS (EVAX) — Financial Flexibility Index

Latest as of December 2025: -0.58x

Evaxion Biotech AS (EVAX) has a Financial Flexibility Index of -0.58x as of December 2025. Free cash flow of $-6.63 Million (operating CF $-6.65 Million minus capex $11.03K) represents -1% of total liabilities ($11.37 Million). Also explore how fast is Evaxion Biotech AS growing its equity to track the company's year-over-year net asset growth rate.

Financial Flexibility Index

-0.58x
Free Cash Flow / Total Liabilities

Free Cash Flow

$-6.63 Million
Operating CF − Capex

Total Liabilities

$11.37 Million
USD

Capital Expenditures

$11.03K
USD

Evaxion Biotech AS Financial Flexibility Index (2018–2025)

Historical Financial Flexibility Index trend for Evaxion Biotech AS across 8 annual periods. Check EVAX strategic asset allocation to assess the company's strategic physical and investment asset allocation.

Annual Financial Flexibility Index for Evaxion Biotech AS (2018–2025)

Year-by-year free cash flow to debt coverage for Evaxion Biotech AS. For the full company profile including market capitalisation, see market cap of Evaxion Biotech AS.

Year Flexibility Index Free Cash Flow (USD) Operating CF Total Liabilities YoY Change
2025 -0.58x $-6.63 Million $-6.65 Million $11.37 Million ▲ +36.2%
2024 -0.92x $-12.94 Million $-12.94 Million $14.14 Million ▲ +8.4%
2023 -1.00x $-17.60 Million $-17.69 Million $17.62 Million ▲ +46.2%
2022 -1.86x $-25.48 Million $-25.77 Million $13.72 Million ▲ +30.3%
2021 -2.66x $-20.57 Million $-21.93 Million $7.73 Million ▼ -8.9%
2020 -2.44x $-12.04 Million $-12.44 Million $4.93 Million ▲ +39.6%
2019 -4.04x $-6.96 Million $-7.03 Million $1.72 Million ▼ -1825.3%
2018 -0.21x $-1.98 Million $-1.99 Million $9.44 Million
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities